Hyperthermia

(redirected from hyperthermic)
Also found in: Dictionary, Thesaurus, Medical, Wikipedia.

hyperthermia

[‚hī·pər′thər·mē·ə]
(physiology)
A condition of elevated body temperature.

Hyperthermia

 

the accumulation of excess heat in the body of humans or animals, with an elevation of body temperature, caused by external factors that hinder the transfer of heat to the external environment or increase heat intake from outside the body. Hyperthermia arises when there is maximum strain on the physiological mechanisms of thermoregulation (perspiration, dilation of cutaneous blood vessels, and so forth); if the causes are not removed, it progresses, ending with heat stroke at a body temperature of approximately 41°-42° C.

Hyperthermia is accompanied by an increase of metabolism and qualitative disturbances of it, loss of water and salts, and disruption of blood circulation and the delivery of oxygen to the brain, causing agitation and sometimes convulsions and fainting. High temperature during hyperthermia is tolerated less readily than it is in other feverish diseases. The development of hyperthermia is promoted by an increase in heat production (for example, during muscular work), disruption of thermoregulation mechanisms (with narcosis, drunkenness, and certain diseases), or age-related failure of these mechanisms (in very young children). Artificial hyperthermia is used in treating certain nervous and slowly progressing chronic diseases.

P. N. VESELKIN

References in periodicals archive ?
This study aimed to assess the effect of cooling hyperthermic athletes using a CG, CJ and CG+CJ compared to NC on subsequent manual dexterity and repeat sprint exercise performance.
Hyperthermic intraperitoneal intraoperative chemotherapy for peritoneal carcinomatosis arising from gastric adenocarcinoma.
In 1985, the North American Hyperthermia Society, together with the European Society for Hyperthermic Oncology, and the Japanese Society of Hyperthermic Oncology cooperatively founded the International Journal of Hyperthermia and adopted it as their official journal.
7) Which of the following agents used in hyperthermic intraperitoneal chemotherapy is associated with pulmonary hypertension as an adverse effect?
Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
The "H" in HIPEC stands for hyperthermic, which is a key differentiator from traditional intraperitoneal and intravenous chemotherapy administration.
Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has well established predictors, described techniques, and indications for the treatment of peritoneal surface malignancies; however, the HIPEC portion of the treatment is not standardized by methods or chemotherapeutic agents.
In the present paper, we report about our experience gained with PIPAC since July 2016 at a tertiary cancer center offering all other therapeutic options for peritoneal metastasis, including in particular palliative systemic chemotherapy, intraperitoneal chemotherapy, intraperitoneal virotherapy [28], cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy (HIPEC).
Recent studies indicate promising survival statistics when cytoreductive surgery is used in combination with hyperthermic intraperitoneal chemotherapy (HiPEC), an emerging treatment modality in various peritoneal sarcomatosis such as DSRCT, rhabdomyosarcoma, leiomyosarcoma, gastrointestinal stromal tumors (GISTs), and liposarcoma [3, 16].
Moreover, the presence of clustered MNs within the edges of necrotic lesions could be an evidence of the effectiveness of hyperthermic treatment associated with the administration of MNs.
A fairly recent study described the combination of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) to be effective in prolonging survival in UrC patients with peritoneal metastases [13].